These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26776098)

  • 1. Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer.
    Colloca G; Venturino A; Guarneri D
    Clin Colorectal Cancer; 2016 Sep; 15(3):264-76. PubMed ID: 26776098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
    Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
    Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
    Ottaiano A; Capozzi M; De Divitiis C; De Stefano A; Botti G; Avallone A; Tafuto S
    Acta Oncol; 2017 Mar; 56(3):377-383. PubMed ID: 28256961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
    Yang ZY; Yuan JQ; Di MY; Zheng DY; Chen JZ; Ding H; Wu XY; Huang YF; Mao C; Tang JL
    PLoS One; 2013; 8(3):e57528. PubMed ID: 23472089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Barni S
    Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):124-31. PubMed ID: 25865683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
    Jin SF; Fan ZK; Pan L; Jin LM
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
    Abou-Alfa GK; Letourneau R; Harker G; Modiano M; Hurwitz H; Tchekmedyian NS; Feit K; Ackerman J; De Jager RL; Eckhardt SG; O'Reilly EM
    J Clin Oncol; 2006 Sep; 24(27):4441-7. PubMed ID: 16983112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
    Berlin JD; Catalano P; Thomas JP; Kugler JW; Haller DG; Benson AB
    J Clin Oncol; 2002 Aug; 20(15):3270-5. PubMed ID: 12149301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
    Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
    J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer.
    Cao Y; Wu L; Tan A; Liu L; Liao C; Gao F
    Pancreas; 2010 Mar; 39(2):253-5. PubMed ID: 20182311
    [No Abstract]   [Full Text] [Related]  

  • 12. Overall survival of patients with advanced pancreatic cancer improved with an increase in second-line chemotherapy after gemcitabine-based therapy.
    Zhang YD; Yang Q; Jiang ZM; Ma W; Zhou SW; Xie DR
    JOP; 2011 Mar; 12(2):131-7. PubMed ID: 21386638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
    Reni M; Cordio S; Milandri C; Passoni P; Bonetto E; Oliani C; Luppi G; Nicoletti R; Galli L; Bordonaro R; Passardi A; Zerbi A; Balzano G; Aldrighetti L; Staudacher C; Villa E; Di Carlo V
    Lancet Oncol; 2005 Jun; 6(6):369-76. PubMed ID: 15925814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.
    Bria E; Milella M; Gelibter A; Cuppone F; Pino MS; Ruggeri EM; Carlini P; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
    Cancer; 2007 Aug; 110(3):525-33. PubMed ID: 17577216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
    Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
    Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers.
    Klapdor R; Seutter E; Lang-Pölckow EM; Reichle H; Hinrichs A
    Anticancer Res; 1999; 19(4A):2459-69. PubMed ID: 10470175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
    Dig Liver Dis; 2014 May; 46(5):452-9. PubMed ID: 24565950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
    Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
    Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
    Liu Y; Huang QK; Hong WD; Wu JM; Sun XC
    Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.